# KAPA catalysts: Kairos Pharma, LTD. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/kapa/catalysts

> Kairos Pharma, LTD. (KAPA) has no upcoming catalysts in this calendar. The latest recorded is the carotuximab interim data readout, October 6, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for KAPA?

Kairos Pharma, LTD. (KAPA) has no upcoming catalysts in this calendar. The latest recorded is the carotuximab interim data readout, October 6, 2026. Press release filed with the SEC (EX-99): "ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)." [Calendar and source filings](https://sec-api.dev/companies/kapa/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001493152-26-045844, https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-10-06. Cite: https://sec-api.dev/companies/kapa/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Kairos Pharma, LTD. |
| Ticker | KAPA (NYSE) |
| SEC CIK | 1962011 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/kapa |

## Cash runway

Cash $3.1M as of 2026-09-30; quarterly burn $979K; about 9.6 months of runway at that rate (XBRL company facts, accession 0001493152-26-051822).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2023 | [Prostate trial start](https://sec-api.dev/pdufa/prostate) | KAPA |  | completed | "As a result, in September 2023 we began enrolling patients for a Phase 1 trial for non-small cell lung cancer and also began enrolling patients in a randomized, multi-institutional Phase 2 trial for prostate cancer." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1962011/000164117225005602/forms-1.htm)) |
| Q2 2025 | [Carotuximab interim data readout](https://sec-api.dev/pdufa/carotuximab) | KAPA |  | scheduled | "We are aiming to be able to discuss safety and interim efficacy results toward the end of the second quarter 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/ex99-1.htm)) |
| September 18, 2025 | [Carotuximab interim data readout](https://sec-api.dev/pdufa/carotuximab) | KAPA |  | scheduled | "September 11, 2025, Kairos Pharma, Ltd., a Delaware corporation (the "Company"), issued a press release announcing that it will host a premier KOL event on Thursday, September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315225013040/form8-k.htm)) |
| October 6, 2026 | [Carotuximab interim data readout](https://sec-api.dev/pdufa/carotuximab) | KAPA | metastatic castration-resistant prostate cancer | completed, positive | "ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/ex99-1.htm)) |

## Drugs

- [Carotuximab](https://sec-api.dev/pdufa/carotuximab): metastatic castration-resistant prostate cancer
- [Prostate](https://sec-api.dev/pdufa/prostate): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/kapa/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KAPA catalysts: Kairos Pharma, LTD. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/kapa/catalysts

```bibtex
@misc{secapidev_companies_kapa_catalysts_20261116,
  title        = {KAPA catalysts: Kairos Pharma, LTD. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/kapa/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_kapa_catalysts_20261116","title":"KAPA catalysts: Kairos Pharma, LTD. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/kapa/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
